XML 85 R19.htm IDEA: XBRL DOCUMENT
v3.20.1

Stock-Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2019
Share-based Payment Arrangement [Abstract] |
Stock-Based Compensation | NOTE 13. STOCK-BASED COMPENSATION The Company recorded pretax compensation expense related to the grant of stock options and restricted stock issued of $2,112,090 and $2,272,656 for the years ended December 31, 2019 and 2018, respectively. As of December 31, 2019, the Company had adopted seven separate stock option and restricted stock plans: (i) the 2005 Stock Option and Restricted Stock Plan (the “2005 Plan”), (ii) the 2006 Stock Option and Restricted Stock Plan (the “2006 Plan”), (iii) the 2007 Stock Option and Restricted Stock Plan (the “2007 Plan”), (iv) the 2008 Stock Option and Restricted Stock Plan (the “2008 Plan”), (v) the 2011 Stock Option and Restricted Stock Plan (the “2011 Plan”), (vi) the 2013 Stock Option and Restricted Stock Plan (the “2013 Plan”), (vii) the 2015 Stock Option and Restricted Stock Plan (the “2015 Plan”) and (vii) the 2018 Stock Option and Restricted Stock Plan (the “2018 Plan”). The 2005 Plan, 2006 Plan, 2007 Plan, 2008 Plan, 2011 Plan, 2013 Plan, 2015 Plan and 2018 Plan are referred to as the “Plans.” These Plans permit the grant of stock options or restricted stock to its employees, non-employee directors and others for up to a total of 4,175,000 shares of common stock. The 2005 Plan terminated during 2015 with 19,678 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2005 Plan that remain unexercised and outstanding as of December 31, 2019 total 8,063. The 2006 Plan terminated during 2016 with 24,662 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2006 Plan that remain unexercised and outstanding as of December 31, 2019 total 42,812. The 2007 Plan terminated during 2017 with 88,401 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2007 Plan that remain unexercised and outstanding as of December 31, 2019 total 6,250. The 2008 Plan terminated during 2018 with 8,249 shares not awarded or underlying options, which shares are now unavailable for issuance. Stock options granted under the 2008 Plan that remain unexercised and outstanding as of December 31, 2019 total 32,250. The Company believes that such awards better align the interests of our employees with those of its stockholders. Option awards have been granted with an exercise price equal to the market price of its stock at the date of grant with such option awards generally vesting based on the completion of continuous service and having ten-year contractual terms. These option awards typically provide for accelerated vesting if there is a change in control (as defined in the Plans). The Company has registered all shares of common stock that are issuable under its Plans with the SEC. A total of 629,186 shares remained available for awards under the various Plans as of December 31, 2019. The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model. Activity in the various Plans during the years ended December 31, 2019 and 2018 is reflected in the following table:
Options |  | Number of Shares |  |  | Weighted Average Exercise Price |
Outstanding at January 1, 2018 |  |  | 350,269 |  |  | $ | 13.44 |
Granted |  |  | 160,000 |  |  |  | 2.20 |
Exercised |  |  | — |  |  |  | — |
Forfeited |  |  | (76,257 | ) |  |  | (45.52 | )
Outstanding at December 31, 2018 |  |  | 434,012 |  |  | $ | 4.62 |
Exercisable at December 31, 2018 |  |  | 354,012 |  |  | $ | 5.17 |
Options |  | Number of Shares |  |  | Weighted Average Exercise Price |
Outstanding at January 1, 2019 |  |  | 434,012 |  |  | $ | 4.62 |
Granted |  |  | 180,000 |  |  |  | 3.01 |
Exercised |  |  | — |  |  |  | — |
Forfeited |  |  | (24,887 | ) |  |  | (13.78 | )
Outstanding at December 31, 2019 |  |  | 589,125 |  |  | $ | 3.74 |
Exercisable at December 31, 2019 |  |  | 499,125 |  |  | $ | 3.87 |
The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model. The total estimated grant date fair value stock options issued during the year ended December 31, 2019 and 2018 was $436,217 and $284,384, respectively. The Company has utilized the following assumptions in its Black-Scholes option valuation model to calculate the estimated grant date fair value of the options during the years ended December 31, 2019 and 2018:.
|  | 2019 |  |  | 2018 |
|  | Assumptions |  |  | Assumptions |
Volatility – range |  |  | 107.6 | % |  |  | 107.5 | %
Risk-free rate |  |  | 2.23 | % |  |  | 2.74 | %
Contractual term |  |  | 5.5 years |  |  |  | 5.5 years |
Exercise price |  | $ | 3.01 |  |  | $ | 2.20 |
The Plans allow for the cashless exercise of stock options. This provision allows the option holder to surrender/cancel options with an intrinsic value equivalent to the purchase/exercise price of other options exercised. There were no shares surrendered pursuant to cashless exercises during the years ended December 31, 2019 and 2018. At December 31, 2019 and 2018, the aggregate intrinsic value of options outstanding was approximately $-0- and $76,800, respectively, and the aggregate intrinsic value of options exercisable was approximately $-0- and $76,800, respectively. No options were exercised in the years ended December 31, 2019 and 2018. As of December 31, 2019, the unrecognized portion of stock compensation expense on all existing stock options was $181,757 and will be recognized over the next five months. The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable options under the Company’s option plans as of December 31, 2019:
|  |  | Outstanding options |  | Exercisable options |
Exercise price range |  |  | Number of options |  |  | Weighted average remaining contractual life |  | Number of options |  |  | Weighted average remaining contractual life |
$ | 0.01 to $3.49 |  |  |  | 470,313 |  |  | 8.4 years |  |  | 380,313 |  |  |  | 8.1 years |
$ | 3.50 to $4.99 |  |  |  | 66,875 |  |  | 4.3 years |  |  | 66,875 |  |  |  | 4.3 years |
$ | 5.00 to $6.49 |  |  |  | — |  |  | — years |  |  | — |  |  |  | — years |
$ | 6.50 to $7.99 |  |  |  | 8,437 |  |  | 1.8 years |  |  | 8,437 |  |  |  | 1.8 years |
$ | 8.00 to $9.99 |  |  |  | 2,500 |  |  | 1.4 years |  |  | 2,500 |  |  |  | 1.4 years |
$ | 10.00 to $19.99 |  |  |  | 39,750 |  |  | 1.0 years |  |  | 39,750 |  |  |  | 1.0 years |
$ | 20.00 to $24.99 |  |  |  | 1,250 |  |  | 0.1 years |  |  | 1,250 |  |  |  | 0.1 years |
|  |  |  |  | 589,125 |  |  | 7.3 years |  |  | 499,125 |  |  |  | 6.9 years |
Restricted stock grants. The Board of Directors has granted restricted stock awards under the Plans. Restricted stock awards are valued on the date of grant and have no purchase price for the recipient. Restricted stock awards typically vest over one to four years corresponding to anniversaries of the grant date. Under the Plans, unvested shares of restricted stock awards may be forfeited upon the termination of service to or employment with the Company, depending upon the circumstances of termination. Except for restrictions placed on the transferability of restricted stock, holders of unvested restricted stock have full stockholder’s rights, including voting rights and the right to receive cash dividends. A summary of all restricted stock activity under the equity compensation plans for the years ended December 31, 2019 and 2018 is as follows:
|  | Number of Restricted shares |  |  | Weighted average grant date fair value |
Nonvested balance, January 1, 2018 |  |  | 791,725 |  |  | $ | 4.37 |
Granted |  |  | 484,500 |  |  |  | 2.27 |
Vested |  |  | (470,175 | ) |  |  | (3.83 | )
Forfeited |  |  | (33,900 | ) |  |  | (4.04 | )
Nonvested balance, December 31, 2018 |  |  | 772,150 |  |  | $ | 3.40 |
|  | Number of Restricted shares |  |  | Weighted average grant date fair value |
Nonvested balance, January 1, 2019 |  |  | 772,150 |  |  | $ | 3.40 |
Granted |  |  | 522,110 |  |  |  | 2.91 |
Vested |  |  | (774,015 | ) |  |  | (3.35 | )
Forfeited |  |  | (5,370 | ) |  |  | (3.46 | )
Nonvested balance, December 31, 2019 |  |  | 514,875 |  |  | $ | 2.97 |
The Company estimated the fair market value of these restricted stock grants based on the closing market price on the date of grant. As of December 31, 2019, there were $379,623 of total unrecognized compensation costs related to all remaining non-vested restricted stock grants, which will be amortized over the next 12 months in accordance with their respective vesting scale. The nonvested balance of restricted stock vests as follows:
Years ended |  | Number of shares |
2020 |  |  | 264,750 |
2021 |  |  | 250,125 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration